ClinicalTrialsFinder
RecruitingNCT07227155

The HOPE Biobank Resource (BMT CTN 2402 HOPE)

Hematopoietic Cell Transplant and Gene Therapy for Non-Malignant Blood Disorders Biobank Resource (BMT CTN 2402)

Sponsor

Medical College of Wisconsin

Enrollment

375 participants

Start Date

May 15, 2026

Study Type

OBSERVATIONAL

Conditions

Bone Marrow FailureHemoglobinopathiesAplastic Anemias

Summary

A prospective, multicenter study that will establish a repository of biospecimens and clinical data from patients undergoing hematopoietic stem cell transplant (HCT) or gene therapy (GT) for treatment of non-malignant blood diseases.

Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with aplastic anemias, bone marrow failure, and other related conditions. The study is currently recruiting participants at 6 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(6)

University of Florida

Gainesville, Florida, United States

Oregon Health and Science University

Portland, Oregon, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Baylor College of Medicine

Houston, Texas, United States

Fred Hutchinson Cancer Center

Seattle, Washington, United States

Children's Hospital of Wisconsin

Milwaukee, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07227155

Related Trials

Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

NCT016660801 location

Allo HSCT for High Risk Hemoglobinopathies

NCT068723331 location

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

NCT031289964 locations

Discarded Bone Marrow for Hematology Research

NCT046712121 location

Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

NCT068394561 location